{
    "RADCURE-3740": {
        "recruit-recruiter": "1. Radiation Oncologist - Your expertise is strictly limited to radiation therapy planning and dosing for head and neck squamous cell carcinoma, especially HPV-negative cases involving the retromolar trigone. - Hierarchy: Radiation Oncologist",
        "question": "Age: 66.0, Sex: Male, ECOG PS: ECOG 0, Smoking PY: 40, Smoking Status: Current, Ds Site: Lip & Oral Cavity, Subsite: Retromolar Trigone, T: T2, N: N0, M : M0, Stage: II, Path: Squamous Cell Carcinoma, HPV: Negative, Tx Modality: RT alone, Chemo? : none, Dose: 70.0, Fx: 35, Local: none, Regional: none, Distant: Possible, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "think-initial_assessment-radiation oncologist": "<think> Okay, let's break this down. The patient is a 66-year-old male with a good performance status (ECOG 0). He's a current smoker with a 40 pack-year history. The tumor is in the retromolar trigone, which is part of the lip and oral cavity. It's a T2, N0, M0 squamous cell carcinoma, stage II. HPV is negative. Treatment was RT alone (70 Gy in 35 fractions), no chemo. Distant metastasis is possible, but no local or regional recurrence noted.\n\nFirst, HPV-negative head and neck cancers, especially oral cavity, tend to have worse prognosis compared to HPV-positive oropharyngeal cases. The retromolar trigone can be tricky due to its location, but since it's T2 and N0, that's early stage. However, smoking is a significant risk factor here—current smoker with heavy history might impact overall survival due to comorbidities or higher risk of secondary cancers.\n\nRadiation dose of 70 Gy in 35 fractions is standard for definitive treatment. But without concurrent chemo, which is often recommended for higher risk features. But since it's stage II (T2N0), maybe chemo wasn't indicated here. However, smoking and HPV-negative status might still portend a higher risk of recurrence or distant spread. The mention of possible distant metastasis raises a red flag—maybe there's suspicion of distant disease, which would lower survival probability. \n\nBut wait, the M stage is M0. So distant metastasis is possible, but not confirmed? Maybe it's under investigation. If distant mets are present, survival drops significantly. But if it's just a possibility without confirmation, maybe the patient is still under follow-up. Also, considering the patient's age and smoking, other comorbidities like cardiovascular or pulmonary issues could affect survival. \n\nIn terms of radiation outcomes, local control for T2N0 with RT alone in oral cavity: 5-year survival for stage II oral cavity is around 60-70%, but HPV-negative and smoking could lower that. However, if there's a possible distant spread, even if not confirmed, the prognosis would be worse. But since the question is about survival, and the data given doesn't confirm distant metastasis (M0), but just \"possible\", maybe the patient is alive. However, heavy smoking and HPV-negative status might lead to higher chances of death from the disease or other causes. \n\nWait, but the treatment was completed, and no local or regional recurrence. So if the RT was successful in controlling the primary and nodes, and distant is possible but not confirmed, maybe the patient is alive. However, the possible distant could imply later development. Without knowing the time frame, but assuming this is after treatment. If distant mets are possible but not present at staging, maybe the patient is still alive but at higher risk. However, survival in such cases depends on whether distant mets actually develop. If they do, the prognosis is poor. But the answer is binary. \n\nConsidering the factors: stage II, HPV-negative, smoker, treated with RT alone. Studies suggest that for oral cavity cancers, the 5-year overall survival for stage II is around 50-70%, but smoking and HPV-negative (though HPV is less prognostic here than in oropharynx) could lower that. Without chemo, but in early stages, maybe RT alone is sufficient. However, if distant is possible, maybe the patient has since developed metastases. But given the info provided, M is M0. So the answer would lean towards alive, but considering all factors, maybe higher risk. But with current info, M0 and no recurrence, so likely alive.",
        "initial_assessment-radiation oncologist": "Answer:Alive",
        "Round 1-role-comment": "radiation oncologist:alive",
        "Round 1-num_agents": 1,
        "think-Round 2-Turn 1-discuss-participate-radiation oncologist": "<think> Okay, let's go through this step by step. The patient is a 66-year-old male with a squamous cell carcinoma of the retromolar trigone, which is part of the lip and oral cavity. He's HPV-negative, which is important because HPV status significantly affects prognosis in head and neck cancers. HPV-positive tumors generally have a better response to treatment and better survival outcomes, so being negative here might be a negative prognostic factor.\n\nHis T stage is T2, N0, M0, making it stage II. He's receiving radiation therapy alone at a dose of 70 Gy in 35 fractions. No chemotherapy is being given. His ECOG performance status is 0, meaning he's fully active, which is a positive factor. However, he's a current smoker with a 40 pack-year history, which is another negative prognostic factor as smoking can impair treatment response and increase the risk of recurrence or secondary cancers.\n\nThe previous opinion from another radiation oncologist suggests \"Alive.\" Now, considering the treatment plan, the dose of 70 Gy in 35 fractions is standard for definitive radiotherapy in head and neck cancers. Since it's a localized T2N0 lesion, radiation alone could be adequate, especially if the patient isn't a candidate for surgery or concurrent chemotherapy. However, the lack of chemotherapy might be a point to consider. For locally advanced cases, concurrent chemoradiation is typically recommended, but this is stage II, which might not require chemo. Still, the smoking status and HPV negativity could argue for a more aggressive approach, but that's outside the scope of the current treatment plan.\n\nThe possible distant metastasis is noted, but with M0, that's not confirmed. The absence of local or regional recurrence is positive. Given the stage and treatment, the 5-year survival for stage II oral cavity cancers can vary, but with proper treatment, it's reasonable to expect survival. The negative HPV status and smoking could lower the survival probability compared to HPV-positive patients, but in the absence of other high-risk features, the radiation oncologist's opinion of \"Alive\" seems plausible.\n\nSince the existing opinion from another radiation oncologist aligns with standard practice and there's no conflicting data from other specialties mentioned, there might not be a need for additional experts unless there's uncertainty in the treatment approach or staging. However, the case seems straightforward from a radiation oncology perspective. If the team is confident in the staging and treatment plan, then no further consultation is needed. But if there's any doubt about the staging (e.g., possible distant metastasis needing further imaging), a medical oncologist or radiologist might be consulted, but the question here is whether I, as a radiation oncologist, need to talk to another expert. Since the existing opinion is already from a radiation oncologist and the case fits within standard protocols, the answer would be no.",
        "Round 2-Turn 1-discuss-participate-radiation oncologist": "Answer:no",
        "think-Round 2-Turn 1-ask_gap-radiation oncologist": "<think> Okay, let's break this down. The patient has a head and neck squamous cell carcinoma, specifically in the retromolar trigone, HPV-negative. They're a current smoker with a 40-pack-year history, T2N0M0 Stage II, treated with RT alone (70 Gy in 35 fractions). The question is whether additional specialists are needed beyond the current team, which includes a radiation oncologist.\n\nFirst, considering the treatment modality: RT alone was used here. For HPV-negative tumors, especially in smokers, concurrent chemoradiation is often recommended even in early stages due to higher aggressiveness. However, this patient didn't receive chemo. The radiation oncologist's input is covered, but maybe a medical oncologist's opinion is needed to assess if chemotherapy was appropriately omitted. Also, the patient is a current smoker, which impacts prognosis and treatment tolerance. A smoking cessation specialist could be beneficial. Surgical evaluation might also be relevant for resectability, so an ENT surgeon's input. Additionally, distant metastasis is possible; maybe a radiologist for imaging review or a medical oncologist for systemic therapy. Since the current team only has a radiation oncologist, adding these specialists could address gaps in chemotherapy decision-making, surgical options, smoking cessation, and metastatic workup.",
        "Round 2-Turn 1-ask_gap-radiation oncologist": "---\nAnswer: yes\nReason: multidisciplinary input for chemo consideration, smoking cessation, and surgical evaluation\n---",
        "Round 2-Turn 1-gap_identified-assistant": "Unique, useful, and specific expert recommendations extracted:\n\n- Multidisciplinary input for chemotherapy consideration  \n- Smoking cessation consultation  \n- Surgical evaluation",
        "Round 2-Turn 1-gap_recruit-recruiter": "1. Medical Oncologist - Your expertise is strictly limited to systemic therapy decisions, including chemotherapy and immunotherapy in head and neck cancers. - Hierarchy: Medical Oncologist == Radiation Oncologist\n2. Surgical Oncologist (Recurrence/Secondary Cancers) - Your expertise is strictly limited to evaluating surgical options for primary and recurrent malignancies in head and neck cancers, including the retromolar trigone. - Hierarchy: Surgical Oncologist == Radiation Oncologist\n3. Smoking Cessation Specialist - Your expertise is strictly limited to counseling and managing smoking cessation in patients with head and neck cancers to improve treatment outcomes. - Hierarchy: Smoking Cessation Specialist -> Radiation Oncologist",
        "think-Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "<think> Okay, let's start by looking at the patient's details. He's 66, male, ECOG PS 0, which is good—means he's fully active. He's a current smoker with a 40 pack-year history. The tumor is in the retromolar trigone, which is part of the lip and oral cavity. The stage is II (T2N0M0), squamous cell carcinoma, HPV-negative. Treatment was RT alone with 70 Gy in 35 fractions, no chemo. Now, there's a possible distant metastasis.\n\nHmm, HPV-negative oral cavity cancers generally have a worse prognosis compared to HPV-positive oropharyngeal cases. Since this is T2N0, the primary treatment for early-stage oral cavity cancer is usually surgery followed by adjuvant therapy if needed, or definitive radiation if surgery isn't feasible. But here, they went with RT alone. For stage II, maybe surgery wasn't an option, or they opted for radiation. However, the absence of chemotherapy might be a factor. \n\nCurrent guidelines for locally advanced head and neck cancer (which this isn't, since it's stage II) often recommend concurrent chemoradiation. But for early stages, especially if resected with clear margins, adjuvant therapy might not be needed. However, if they're using definitive RT alone in a non-surgical candidate, the outcomes might vary. The possible distant metastasis is concerning. HPV-negative tumors are more aggressive and have higher rates of distant failure. \n\nSmoking is a negative prognostic factor, and continued smoking can reduce treatment efficacy. The patient's age isn't too old, but smoking history adds to the risk. The possible distant recurrence would significantly impact survival. If distant metastasis is confirmed, the prognosis would be poor, shifting to palliative care. However, the question states \"Distant: Possible,\" which might mean it's suspected but not confirmed. Without confirmed metastasis, maybe the initial treatment could still be effective. But given the high-risk features (HPV-negative, smoking, possible distant spread), the survival probability might be lower. \n\nBut wait, the initial treatment was RT alone. In cases where chemotherapy isn't given, especially in higher-risk patients, recurrence rates might be higher. However, for T2N0, maybe RT alone was considered sufficient. But with possible distant metastasis now, even if the primary is controlled, distant spread would lower survival. However, the answer options are Alive or Dead. If there's possible distant metastasis but not confirmed, maybe the patient is still alive but under evaluation. Alternatively, if the metastasis is confirmed, the prognosis is worse. But the data given here isn't clear on confirmation. \n\nIn clinical trials, the 5-year survival for stage II oral cavity cancer with appropriate treatment is around 60-70%, but HPV-negative and smoking could lower that. If distant metastasis occurs, median survival drops to under a year. But since it's only \"possible,\" maybe the patient is still alive at the time of assessment. However, without systemic therapy (chemo or immunotherapy), the control of micrometastases is less, increasing the risk of distant failure. \n\nAs a medical oncologist, the absence of systemic therapy in a high-risk patient (smoking, HPV-negative) might be a point of consideration. For higher stages, concurrent chemo is standard, but in stage II, it's not typically indicated. However, if there's a high risk of recurrence, maybe adjuvant chemo or immunotherapy could be considered, but that's beyond the initial treatment described. \n\nSince the treatment was RT alone and there's a possible distant recurrence, but we don't know the timeline. If the patient is being evaluated now with possible distant mets, maybe he's still alive but with a guarded prognosis. Alternatively, if the distant metastasis was confirmed and led to death, the answer would be Dead. But the data says \"Distant: Possible\"—so maybe it's suspected but not confirmed yet, leading to ongoing monitoring. \n\nGiven the information, I might lean towards Alive, assuming that the possible distant metastasis is under evaluation and the patient is still alive at this point. However, the high-risk factors could mean a lower survival probability. But without confirmation of distant spread, the answer might be Alive.",
        "Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "Answer:Alive",
        "think-Round 2-Turn 1-gap_recruited_assessment-surgical oncologist (recurrence/secondary cancers)": "<think> Okay, let's start by looking at the patient's details. He's a 66-year-old male with a current smoking habit of 40 pack-years. The primary site is the retromolar trigone, which is part of the lip and oral cavity. The tumor is T2, N0, M0, so stage II squamous cell carcinoma. HPV is negative, which is a negative prognostic factor in head and neck cancers.\n\nTreatment given was RT alone (70 Gy in 35 fractions), no chemotherapy. The current issues are possible distant metastasis. Distant spread in head and neck cancers, especially with HPV-negative status and heavy smoking, is concerning. The patient's ECOG PS is 0, which is good, but the possible distant metastasis would significantly impact survival. \n\nAs a surgical oncologist focused on recurrence and secondary cancers, I know that for retromolar trigone tumors, surgery might be considered for primary treatment, but this patient received RT alone. If there's a recurrence, salvage surgery could be an option, but the presence of possible distant metastasis complicates things. Distant metastasis usually indicates a poorer prognosis, and surgical options would be limited unless it's a solitary metastasis. However, the question is about survival probability. \n\nIn HPV-negative SCC with distant spread, the 5-year survival drops considerably. Even though the primary was treated with RT, the possible distant metastasis suggests advanced disease progression. The heavy smoking history also contributes to higher risk of treatment resistance and secondary cancers. Without effective systemic therapy (he didn't receive chemo initially), the outcome might be worse. \n\nSo, considering the possible distant metastasis and the factors (HPV-negative, smoking), the survival probability is likely lower. The answer here would be Dead.",
        "Round 2-Turn 1-gap_recruited_assessment-surgical oncologist (recurrence/secondary cancers)": "Answer:Dead",
        "think-Round 2-Turn 1-gap_recruited_assessment-smoking cessation specialist": "<think> Okay, let's break this down. The patient is a 66-year-old male with a history of heavy smoking (40 pack-years) and currently still smoking. He has squamous cell carcinoma of the retromolar trigone, stage II (T2N0M0), HPV-negative. He's receiving radiation therapy alone at 70 Gy over 35 fractions. The distant metastasis is noted as possible.\n\nAs a smoking cessation specialist, my focus is on how continued smoking affects his treatment outcomes. Smoking during radiation therapy for head and neck cancer is known to reduce treatment efficacy. It can impair wound healing, increase side effects like mucositis, and lower overall survival rates. HPV-negative status is already a negative prognostic factor compared to HPV-positive cancers. Additionally, possible distant metastasis might indicate a higher risk of progression.\n\nContinued smoking could contribute to a higher likelihood of treatment complications and possibly lower the chances of controlling both local and distant disease. Even though the stage is II, the combination of current smoking, HPV-negative status, and possible distant spread might negatively impact survival. Encouraging cessation could improve his response to RT and overall prognosis, but given the current data, the ongoing smoking habit might reduce survival probability.",
        "Round 2-Turn 1-gap_recruited_assessment-smoking cessation specialist": "Answer:Dead",
        "think-Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-medical oncologist": "<think> Okay, let's start by reviewing the patient's details again. The patient is a 66-year-old male with a current smoking status and a 40 pack-year history. The diagnosis is squamous cell carcinoma of the retromolar trigone, stage II (T2N0M0), HPV-negative. Treatment was RT alone (70 Gy in 35 fractions) with no chemotherapy. Distant metastasis is possible, and there's no mention of second cancers.\n\nThe radiation oncologist and medical oncologist both say \"Alive,\" while the surgical oncologist and smoking cessation specialist say \"Dead.\" As a medical oncologist focused on systemic therapy, I need to consider why there's a discrepancy. The surgical oncologist might be concerned about recurrence or secondary cancers, which are possible given the patient's smoking history. The smoking cessation specialist's input might relate to ongoing risk factors affecting survival.\n\nHowever, in my role, I focus on systemic therapy decisions. The patient didn't receive chemotherapy, which could be a consideration here. For stage II HPV-negative oral cavity cancer, the standard is surgery followed by adjuvant therapy if needed, but RT alone might be used in some cases. However, the absence of systemic therapy could impact outcomes, especially with high-risk features like continued smoking. Distant metastasis possibility is concerning, but without confirmed metastasis, prognosis might still vary. Since two oncology experts say \"Alive,\" and my role is systemic therapy, even though the patient didn't receive chemo, maybe the RT was sufficient for local control. However, the risk factors (smoking, HPV-negative) could lead to worse outcomes. But the current answer from my perspective, considering possible distant spread but no confirmed, and initial treatment, might still lean towards Alive. The conflicting opinions from other specialists make me think about additional factors. But since my expertise is systemic therapy, and the patient didn't get chemo, maybe I don't need another expert. Wait, the question is whether to consult another expert. The current split is 2 Alive, 2 Dead. Maybe a pathologist to confirm HPV status again? Or a radiologist for imaging details on distant mets? But the prompt says to stay within my role. Since systemic therapy decisions might not require more experts here, perhaps the answer is no. But considering the possible distant metastasis, maybe a radiologist's input would help. However, the original question is whether to talk to an additional expert. The existing team has radiation, medical, surgical oncologists, and smoking specialist. If the distant metastasis is possible but not confirmed, perhaps the medical oncologist's role would involve considering systemic therapy if confirmed. Since the current info is \"possible,\" maybe further input from a radiologist or diagnostic expert is needed. But the question is whether I, as a medical oncologist, need to consult another expert beyond the current team. Since the surgical oncologist's opinion on recurrence and smoking specialist's input on cessation's impact are already considered, and my focus is on systemic therapy, perhaps no additional experts are needed. Therefore, answer \"no.\"",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-medical oncologist": "Answer:no",
        "think-Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-surgical oncologist (recurrence/secondary cancers)": "<think> Okay, let's start by reviewing the case again. The patient is a 66-year-old male with a current smoking history of 40 pack-years, which is significant. The tumor is located in the retromolar trigone, which is part of the oral cavity. The stage is T2N0M0, so it's a Stage II squamous cell carcinoma, HPV-negative. He received RT alone at a dose of 70 Gy in 35 fractions, no chemotherapy. The distant metastasis is listed as possible.\n\nNow, looking at the opinions from the team. The radiation oncologist and medical oncologist both say \"Alive,\" while the surgical oncologist (me) and the smoking cessation specialist say \"Dead.\" As a surgical oncologist specializing in recurrence and secondary cancers, my initial assessment was \"Dead,\" probably considering factors like high risk of recurrence due to continued smoking, HPV-negative status which is a worse prognostic factor, and possible distant metastasis. However, the other oncologists are more optimistic, maybe focusing on the early stage (II) and successful RT treatment with no local or regional recurrence noted. The smoking cessation specialist's \"Dead\" might relate to the ongoing smoking's impact on overall survival, not just cancer recurrence.\n\nWait, but the patient is a current smoker, which complicates healing and increases recurrence risk. HPV-negative HNSCC has poorer outcomes. The RT dose is standard (70 Gy), but without chemo, which is sometimes used in advanced cases. Since this is T2N0, maybe chemo wasn't indicated. However, possible distant metastasis is noted, which if confirmed, would change the stage to IV and prognosis worse. But the question is about survival, and the answer options are Alive or Dead. The possible distant metastasis might not be confirmed yet, so the stage is still II. But the fact that it's possible suggests imaging findings suspicious but not confirmed. If there are distant mets, that's bad. However, the other oncologists might be considering that without confirmed mets, the patient could still be alive. But as a surgical oncologist, I might be more concerned about the aggressive nature of the tumor (HPV-negative, smoking) leading to early recurrence or secondary cancers, especially since the patient is still smoking. The smoking cessation specialist's input about ongoing smoking contributing to mortality from other causes (like cardiovascular or lung disease) might also factor in. \n\nBut given that the patient has possible distant metastasis, maybe that's the key. If distant mets are present, survival is worse. However, the answer options are binary. The radiation and medical oncologists might be more optimistic if the distant mets are not confirmed yet, while the surgical oncologist is considering the high likelihood of progression. The smoking cessation specialist's \"Dead\" could be due to comorbidities from smoking, not directly the cancer. But the question is about survival in the context of the cancer treatment. \n\nIn the initial response, I answered \"Dead,\" but the majority here (two vs two, but including different specialties) might not reach consensus. However, the user is asking if I want to consult additional experts. The existing team has radiation, medical, surgical, and smoking cessation. Maybe a pathologist or a radiologist to clarify the possible distant metastasis? If the distant mets are confirmed, that's a game-changer. Alternatively, a palliative care specialist's input on prognosis. But the question is whether to consult another expert. Since there's a split in opinions and the possible distant mets is a critical factor, consulting a radiologist or a diagnostic imaging expert to confirm the presence of distant metastasis might be necessary. However, in the context of the given scenario, the user is asking if I (as the surgical oncologist) want to talk to another expert based on the existing opinions. Since there's a tie between Alive and Dead, perhaps seeking a tie-breaker, but the available specialties might be covered. Alternatively, given that possible distant mets are a key point, maybe a medical oncologist's opinion on systemic therapy options if mets are present. But the medical oncologist already said Alive. Maybe a multidisciplinary tumor board review? But the user's question is about consulting an additional expert. Since the possible distant mets is not confirmed, maybe a radiologist's input is needed. However, the question is whether to add an expert, not to get more tests. Since the existing team has the necessary specialties, and the split is between those focusing on treatment response (radiation/medical oncologists) vs those considering recurrence and comorbidities (surgical oncologist and smoking cessation), perhaps no additional experts are needed. The answer would be no.",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-surgical oncologist (recurrence/secondary cancers)": "Answer:no",
        "think-Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-smoking cessation specialist": "<think> Okay, so I need to figure out whether to consult another expert based on the opinions provided. Let's start by reviewing the case details again. The patient is a 66-year-old male with a 40 pack-year smoking history, currently still smoking. He has squamous cell carcinoma of the retromolar trigone, stage II (T2N0M0), HPV-negative, treated with RT alone (70 Gy in 35 fractions). No chemotherapy. Distant metastasis is possible. The team's opinions are divided: radiation oncologist and medical oncologist say alive, surgical oncologist and smoking cessation specialist (me) say dead.\n\nAs a smoking cessation specialist, my concern is the ongoing smoking. Continued smoking post-diagnosis worsens prognosis by increasing treatment resistance, reducing efficacy of RT, higher recurrence risk, and higher risk of second cancers. HPV-negative status is another negative factor. However, the patient's ECOG PS is 0, which is good, and the tumor is stage II without nodal involvement. But the possible distant metastasis complicates things. The other oncologists might be considering the early stage and successful local treatment, hence their 'Alive' votes. The surgical oncologist's 'Dead' could be due to possible recurrence or metastasis. \n\nGiven the split in opinions, especially between specialties, maybe there's a need for another perspective. However, all relevant specialties (radiation, medical, surgical oncology, and smoking cessation) have already weighed in. The possible distant metastasis is a key factor here. Perhaps a medical oncologist specializing in metastatic disease or a palliative care specialist could offer more insight into the prognosis with possible distant spread. But since the medical oncologist has already given an opinion, maybe that's covered. Alternatively, a radiologist to assess imaging for metastasis confirmation could help, but the case states 'Distant: Possible' which might mean it's not confirmed yet. If metastasis is confirmed, prognosis worsens significantly. But without confirmation, the team might be making educated guesses. \n\nSince the question is whether to consult another expert, considering all the current opinions and the factors involved, maybe the existing team has enough input. However, the possible distant metastasis is a critical point. If there's uncertainty about metastasis presence, consulting a diagnostic radiologist or a metastasis specialist might clarify. But given the available info, the team might have already considered that. Alternatively, if the patient's smoking cessation status isn't improving, perhaps a more intensive intervention is needed, but that's within my role. Since the split remains, but the core specialties have contributed, maybe no additional experts are needed. The answer might hinge on whether distant metastasis is confirmed, which isn't clear here. But based on the given info, the team has covered the main areas. So, perhaps no need for additional experts.",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-smoking cessation specialist": "Answer:no",
        "Round 2-role-comment": "radiation oncologist:alive|medical oncologist:alive|surgical oncologist (recurrence/secondary cancers):dead|smoking cessation specialist:dead",
        "Round 2-num_agents": 4,
        "num_cooperations-panel": 0,
        "decision-Moderator": "('Answer: Alive',)"
    }
}